Biogen took a colossal risk in late 2019. It revived an Alzheimer’s disease drug it had left for dead earlier that year after it appeared to fail two large clinical trials.
The company wasn’t ready to take no for an answer. It had poured years of effort into developing the therapy, then called aducanumab, and was counting on it as its next big therapeutic advance.
